Literature DB >> 10048982

Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model.

J N Cormier1, M C Panelli, J A Hackett, M P Bettinotti, A Mixon, J Wunderlich, L L Parker, N P Restifo, S Ferrone, F M Marincola.   

Abstract

Increasing attention has been devoted to elucidating the mechanism of lost or decreased expression of MHC or melanoma-associated antigens (MAAs), which may lead to tumor escape from immune recognition. Loss of expression of HLA class I or MAA has, as an undisputed consequence, loss of recognition by HLA class I-restricted cytotoxic T cells (CTLs). However, the relevance of down-regulation remains in question in terms of frequency of occurrence. Moreover the functional significance of epitope down-regulation, defining the relationship between MHC/epitope density and CTL interactions, is a matter of controversy, particularly with regard to whether the noted variability of expression of MHC/epitope occurs within a range likely to affect target recognition by CTLs. In this study, bulk metastatic melanoma cell lines originated from 25 HLA-A*0201 patients were analyzed for expression of HLA-A2 and MAAs. HLA-A2 expression was heterogeneous and correlated with lysis by CTLs. Sensitivity to lysis was also independently affected by the amount of ligand available for binding at concentrations of 0.001 to 1 mM. Natural expression of MAA was variable, independent from the expression of HLA-A*0201, and a significant co-factor determining recognition of melanoma targets. Thus, the naturally occurring variation in the expression of MAA and/or HLA documented by our in vitro results modulates recognition of melanoma targets and may (i) partially explain CTL-target interactions in vitro and (ii) elucidate potential mechanisms for progressive escape of tumor cells from immune recognition in vivo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10048982      PMCID: PMC2072935          DOI: 10.1002/(sici)1097-0215(19990301)80:5<781::aid-ijc24>3.0.co;2-a

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

1.  Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response.

Authors:  Y Sykulev; M Joo; I Vturina; T J Tsomides; H N Eisen
Journal:  Immunity       Date:  1996-06       Impact factor: 31.745

2.  Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells.

Authors:  F M Marincola; L Rivoltini; M L Salgaller; M Player; S A Rosenberg
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1996-07

3.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains.

Authors:  K C Parker; M A Bednarek; J E Coligan
Journal:  J Immunol       Date:  1994-01-01       Impact factor: 5.422

4.  Loss of HLA haplotype and B locus down-regulation in melanoma cell lines.

Authors:  F M Marincola; P Shamamian; R B Alexander; J R Gnarra; R L Turetskaya; S A Nedospasov; T B Simonis; J K Taubenberger; J Yannelli; A Mixon
Journal:  J Immunol       Date:  1994-08-01       Impact factor: 5.422

5.  Expression of gp100 in melanoma metastases resected before or after treatment with IFN alpha and IL-2.

Authors:  C Scheibenbogen; I Weyers; D Ruiter; M Willhauck; A Bittinger; U Keilholz
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1996-09

6.  Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: relevance for epitope specific vaccination protocols.

Authors:  M A Player; K C Barracchini; T B Simonis; L Rivoltini; F Arienti; C Castelli; A Mazzocchi; F Belli; G Parmiani; F M Marincola
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1996-09

7.  Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.

Authors:  Y Kawakami; S Eliyahu; C Jennings; K Sakaguchi; X Kang; S Southwood; P F Robbins; A Sette; E Appella; S A Rosenberg
Journal:  J Immunol       Date:  1995-04-15       Impact factor: 5.422

8.  Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions.

Authors:  F M Marincola; Y M Hijazi; P Fetsch; M L Salgaller; L Rivoltini; J Cormier; T B Simonis; P H Duray; M Herlyn; Y Kawakami; S A Rosenberg
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1996-05

9.  Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo.

Authors:  E Jäger; M Ringhoffer; J Karbach; M Arand; F Oesch; A Knuth
Journal:  Int J Cancer       Date:  1996-05-16       Impact factor: 7.396

10.  Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer.

Authors:  I Yoshino; G E Peoples; P S Goedegebuure; R Maziarz; T J Eberlein
Journal:  J Immunol       Date:  1994-03-01       Impact factor: 5.422

View more
  22 in total

1.  Functional heterogeneity of vaccine-induced CD8(+) T cells.

Authors:  Vladia Monsurrò; Dirk Nagorsen; Ena Wang; Maurizio Provenzano; Mark E Dudley; Steven A Rosenberg; Francesco M Marincola
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

2.  Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma.

Authors:  Kazumasa Hiroishi; Junichi Eguchi; Toshiyuki Baba; Tomoe Shimazaki; Shigeaki Ishii; Ayako Hiraide; Masashi Sakaki; Hiroyoshi Doi; Shojiro Uozumi; Risa Omori; Takuya Matsumura; Tatsuro Yanagawa; Takayoshi Ito; Michio Imawari
Journal:  J Gastroenterol       Date:  2009-11-20       Impact factor: 7.527

Review 3.  Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Authors:  Hung T Khong; Nicholas P Restifo
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

4.  A screening assay to identify agents that enhance T-cell recognition of human melanomas.

Authors:  Timothy J Haggerty; Ian S Dunn; Lenora B Rose; Estelle E Newton; James T Kurnick
Journal:  Assay Drug Dev Technol       Date:  2011-11-15       Impact factor: 1.738

5.  Ran signaling in melanoma: implications for the development of alternative therapeutic strategies.

Authors:  Emilia Caputo; Ena Wang; Anna Valentino; Stefania Crispi; Valeria De Giorgi; Annalisa Fico; Bartolomea Ficili; Mariaelena Capone; AnnaMaria Anniciello; Ernesta Cavalcanti; Gerardo Botti; Nicola Mozzillo; Paolo A Ascierto; Francesco M Marincola; Salvatore Travali
Journal:  Cancer Lett       Date:  2014-11-20       Impact factor: 8.679

6.  High GILT Expression and an Active and Intact MHC Class II Antigen Presentation Pathway Are Associated with Improved Survival in Melanoma.

Authors:  Kenneth H Buetow; Lydia R Meador; Hari Menon; Yih-Kuang Lu; Jacob Brill; Haiyan Cui; Denise J Roe; David J DiCaudo; K Taraszka Hastings
Journal:  J Immunol       Date:  2019-10-07       Impact factor: 5.422

7.  Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition?

Authors:  Simone Kayser; Iris Watermann; Christine Rentzsch; Toni Weinschenk; Diethelm Wallwiener; Brigitte Gückel
Journal:  J Cancer Res Clin Oncol       Date:  2003-06-26       Impact factor: 4.553

8.  Effect of invariant chain on major histocompatibility complex class I molecule expression and stability on human breast tumor cell lines.

Authors:  Xuede Lin; Xiaojian Wang; Haley L Capek; Laura C Simone; Amit Tuli; Chantey R Morris; Adrian J Reber; Joyce C Solheim
Journal:  Cancer Immunol Immunother       Date:  2008-10-01       Impact factor: 6.968

9.  Increased effector-target cell conjugate formation due to HLA restricted specific antigen recognition.

Authors:  Ching Y Voss; Sara Deola; Thomas A Fleisher; Francesco M Marincola
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

10.  Cystatin E/M suppresses legumain activity and invasion of human melanoma.

Authors:  Jon J Briggs; Mads H Haugen; Harald T Johansen; Adam I Riker; Magnus Abrahamson; Øystein Fodstad; Gunhild M Maelandsmo; Rigmor Solberg
Journal:  BMC Cancer       Date:  2010-01-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.